The supplied filings identify this applicant at 3200 N Grandview Blvd., Waukesha, Wisconsin, the address printed on both clearance letters. The two linked records sit in the 510(k) pathway, and the collection as retrieved shows two Substantially Equivalent decisions across two records. That count describes the supplied filings only; it is not a measure of total portfolio, sales or safety performance. The records cover two distinct product codes: QIH for the EchoPAC software submission and IYN for the Vivid systems submission. [1][2][3]
EchoPAC software clearance K261623
K261623 covers EchoPAC Software Only / EchoPAC Plug-in (v211), received May 15, 2026 and decided September 16, 2026 as Substantially Equivalent under the Traditional route. The clearance letter lists regulation 21 CFR 892.2050, Medical Image Management and Processing System, Class II, with product codes QIH and LLZ. The letter states the device employs the same fundamental scientific technology as its predicate and compares it with predicate EchoPAC Software Only / EchoPAC Plug-in (K251342). [1][3]
The earlier K251342 letter, dated July 16, 2025, names the same trade name and the same regulation and product codes, and identifies K220940 as its predicate. That 2025 letter states the submission did not require clinical studies to support substantial equivalence. The 2022 K220940 letter names the same trade name and regulation, with product codes QIH and LLZ. [7][9]
Vivid cardiovascular ultrasound clearance K261313
K261313 covers Vivid Explorer, Vivid Advanced and Vivid Focus, received April 21, 2026 and decided September 2, 2026 as Substantially Equivalent under the Traditional route. The record lists product code IYN, regulation 21 CFR 892.1550 and the advisory committee as Radiology. The applicant contact on the record is Yuan Wang. [2]
GE HealthCare's own press release, dated August 28, 2026, describes the three Vivid systems as additions to its cardiovascular ultrasound portfolio, bringing cSound imaging with capabilities described for routine echocardiography, comprehensive cardiac imaging and interventional care. The same release states that availability of future software releases, including v211, is subject to applicable regulatory clearances and may vary by country. [8]
Applicant identity and brand attribution
The FDA records name GE Medical Systems Ultrasound and Primary Care Diagnostics as the applicant, with Charlotte Joergensen listed as contact on K261623 and the clearance letter. The Vivid press release is published by GE HealthCare Technologies Inc. and uses GE HealthCare branding; the filings themselves do not state a parent-subsidiary relationship, so the link between the applicant and that brand rests on the shared product names rather than an explicit ownership statement in the sources. [1][2][3][8]
EchoPAC product material published by GE HealthCare describes EchoPAC Connect as a marketing name for EchoPAC Plug-in (v206) combined with a GE HealthCare host, and notes that features or products may not be available in all markets. That page concerns v206, not the v211 version cleared in K261623. [10]
Regulatory context for software changes
FDA's Predetermined Change Control Plans page describes a PCCP as covering planned device changes, how the manufacturer will develop, test and implement them, and how impact will be assessed, and notes that FDA may authorize a PCCP within a marketing submission. The page also lists guidance on PCCPs for artificial intelligence-enabled device software functions. None of the linked FDA records states whether either clearance included a PCCP. [6]
